Cold Head Congestion Nighttime and Granisetron injection
Determining the interaction of Cold Head Congestion Nighttime and Granisetron injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using granisetron together with dextromethorphan can increase the risk of a rare but serious condition called the serotonin syndrome, which may include symptoms such as confusion, hallucination, seizure, extreme changes in blood pressure, increased heart rate, fever, excessive sweating, shivering or shaking, blurred vision, muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea, vomiting, and diarrhea. Severe cases may result in coma and even death. You should seek immediate medical attention if you experience these symptoms while taking the medications. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), 5-HT1 receptor agonists (triptans), ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John's wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. According to the manufacturers, development of serotonin syndrome has been reported with 5-HT3 receptor antagonists, primarily during concomitant use of serotonergic drugs but also in overdose. Some of the reported cases were fatal. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.
MANAGEMENT: Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is typically recommended following use of fluoxetine and 2 weeks following use of MAOIs before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.
- "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- "Product Information. Sancuso (granisetron)." ProStrakan Group, Bedminster, NJ.
- "Product Information. Aloxi (palonosetron)." MGI Pharma Inc, Minnetonka, MN.
- "Product Information. Anzemet (dolasetron)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Generic Name: acetaminophen / chlorpheniramine / dextromethorphan / phenylephrine
Brand name: Dimetapp Multi-Symptom Cold and Flu, GNP Tussin Night Time, Cold Head Congestion Nighttime, Cold Multi-Symptom Nighttime, Comtrex Cold & Cough Nighttime, Theraflu Severe Cold Nighttime, Tylenol Cold Head Congestion, Tylenol Childrenâs Plus Flu, Tylenol Childrenâs Plus Multi-Symptom Cold
Synonyms: Acetaminophen, Chlorpheniramine, Dextromethorphan, Phenylephrine Liquid
Generic Name: granisetron
Brand name: Sustol, Kytril, Sancuso
Synonyms: Granisetron
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cold Head Congestion Nighttime-Granisetron Oral, Intravenous
- Cold Head Congestion Nighttime-Granisetron Tablets
- Cold Head Congestion Nighttime-Granisetron transdermal
- Cold Head Congestion Nighttime-Granisetron Transdermal System
- Cold Head Congestion Nighttime-Granisol
- Cold Head Congestion Nighttime-Granix
- Granisetron injection-Cold Medicine Plus
- Granisetron injection-Cold Multi-Symptom Nighttime
- Granisetron injection-Cold Relief Plus
- Granisetron injection-Cold Symptoms Relief Maximum Strength
- Granisetron injection-Cold-EEZE
- Granisetron injection-Coldcough PD Syrup